Bumrungrad Hospital Public Company Limited

Bumrungrad Hospital Public Company Limited owns and operates healthcare-related entities in Thailand and internationally. The company offers diagnostic, therapeutic, and intensive care facilities in a medical center. Its outpatient clinics/centers include allergy, arrhythmia, behavioral health, breastfeeding, breast care, children, dental, diabetes, diagnostic, dialysis, digestive disease, emergency, eye, fertility and IVF, health screening, hearing and balance, heart valve, cancer, hyperbaric oxygen therapy, hypertension, joint replacement, liver, memory, men, nephrology, neuroscience, new life healthy aging, orthopedic, Parkinson's disease and movement disorders, perinatal, physical therapy and rehabilitation, plastic surgery, pulmonary, refractive surgery, robotic scoliosis and surgery, skin, sleep lab, spine, sports medicine and lifestyle, surgical, travel medicine, urology, vitalife, and women's, as well as ear, nose, and throat centers. In addition, the company is involved in the real estate assets holding activities; provision of clinical research services; distribution of pharmaceutical and medical goods in specialized stores; operation of personnel development and training center for healthcare services; and patient referral service business. It operates 580 beds and approximately 56 clinics/centers. The company was founded in 1980 and is headquartered in Bangkok, Thailand.

Bumrungrad Hospital Public Company Limited trades as BUGDF on OTC. The company is classified in Healthcare / Medical - Care Facilities and reports in USD.

The current profile places the business in Medical - Care Facilities. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $25.11B of revenue and $7.51B of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Bumrungrad Hospital Public Company Limited can be compared against peers such as Ambu A/S, Amplifon S.p.A., MediPal Holdings Corporation, MediPal Holdings Corporation, Nihon Kohden Corporation, Ryman Healthcare Limited.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $3.78B, beta of 0.23, and return on equity of +24.6%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

BUGDF currently shows total debt of $487.29M and beta of 0.23. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.bumrungrad.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.